Blood Test for Colon Cancer Improves Chemotherapy Decisions, Study Finds
The study demonstrated that patients who test positive for ctDNA "actually benefit from chemotherapy."
The study demonstrated that patients who test positive for ctDNA "actually benefit from chemotherapy."
The collaboration has produced a custom nucleic acid extraction workflow designed to unlock molecular insights from a novel biospecimen and improve diagnostic utility in gut health conditions.
CITCCA data demonstrate more than 40% of high-risk stage I–III colorectal patients harbor molecular residual disease at clinical landmark, detectable only with ultrasensitive ctDNA testing.
Vibrant Wellness has enhanced its Gut Zoomer microbiome panel with expanded microbial and metabolite testing.
Read MoreA study found that colorectal cancer screening could be boosted by using a rapid, accurate app-read smartphone FIT.
Read MoreNew Day Diagnostics has launched ColoHealth, a physician-mediated blood test for colorectal cancer screening.
Read MoreNatural disasters and the COVID-19 pandemic disrupted colorectal cancer diagnoses in Puerto Rico, leading to a rise in delayed diagnoses.
Read MoreSysmex America will distribute Sentinel Diagnostics SENTiFIT 270 and 800 analyzers in Canada for colorectal cancer (CRC) screening.
Read MoreMainz Biomed is collaborating with Quest Diagnostics to support the commercialization and FDA validation of a stool-based DNA test.
Read MoreA new study highlights the critical role of genomic testing in diagnosing Lynch syndrome and guiding treatment for inherited cancers.
Read MoreColorectal cancer screening, while highly effective, is underutilized among patients at federally qualified health centers (FQHCs).
Read MoreProscia and Owkin announced a partnership to integrate AI-driven MSI screening technology, expanding access to colorectal cancer diagnostics.
Read MoreMultitarget stool DNA testing is a highly sensitive, non-invasive method for colorectal cancer screening, offering a colonoscopy alternative.
Read MoreNew blood tests for colorectal cancer screening are less invasive than colonoscopies but less effective at detecting early cancers.
Read MoreThe FDA approved Exact Sciences’ Cologuard Plus test, a stool DNA test that enhances colorectal cancer and precancerous lesion detection.
Read MoreStool-based tests are promising alternatives to colonoscopy for colorectal cancer screening, addressing global accessibility challenges.
Read MoreA new study emphasizes the potential of advanced sequencing techniques in improving outcomes for CRC patients with rare genetic variants.
Read MoreNew research highlights a lack of awareness regarding family history of colorectal cancer, putting many at risk of undiagnosed colon cancer.
Read More